TP53 and acute myeloid leukemia: In particular, TP53 mutations are associated with inferior response rates, shorter disease response and higher MRD positivity in newly diagnosed AML patients treated with combination of venetoclax and decitabine, highlighting the need for novel therapies in this patient group [73].